EGFR and non-small cell lung carcinoma: Here, we conducted a retrospective study to assess the efficacy and safety of third‐generation EGFR‐TKIs compared with chemotherapy in patients with T790M‐negative EGFR mutated NSCLC progressing on first‐ or second‐generation EGFR‐TKIs treatment.